Phytomedicine Plus, Год журнала: 2024, Номер unknown, С. 100723 - 100723
Опубликована: Дек. 1, 2024
Язык: Английский
APOPTOSIS, Год журнала: 2025, Номер unknown
Опубликована: Янв. 4, 2025
Язык: Английский
Процитировано
1
Journal of Ethnopharmacology, Год журнала: 2024, Номер 333, С. 118466 - 118466
Опубликована: Июнь 15, 2024
Zhishi Xiebai Guizhi Decoction (ZSXBGZD) is a traditional herbal manuscript used to treat cardiovascular disease, including atherosclerosis and coronary heart disease. The decoction has demonstrated its capability protect arteries resist atherosclerosis. Its mechanisms for anti-atherosclerosis effect, nevertheless, remain unknown.
Язык: Английский
Процитировано
7
Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 11
Опубликована: Янв. 15, 2025
Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases, such as myocardial infarction, ischemia, and sudden cardiac death. It characterized by excessive proliferation activation fibroblasts, transformation into myofibroblasts, and, eventually, deposition the extracellular matrix, resulting in heart damage. Currently, modern drugs angiotensin-converting enzyme inhibitors, diuretics, β-blockers can improve clinical treatment, but their therapeutic effect on this disease limited, with obvious side effects high cost. Traditional Chinese medicine (TCM) has advantages multiple targets, low cost, few effects. medicines, Salvia miltiorrhiza, Astragalus, Angelica extracts, patent Qiliqiangxin capsules, Shenqi Yiqi dropping pills, Tongxinluo fibrosis. In review, current Western methods for treating are discussed. The signaling pathways targets involved treatment This review aimed to provide valuable insights ideas both basic research
Язык: Английский
Процитировано
0
Phytomedicine, Год журнала: 2025, Номер unknown, С. 156420 - 156420
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Pharmacognosy Magazine, Год журнала: 2025, Номер unknown
Опубликована: Янв. 27, 2025
Background Myocardial fibrosis following myocardial infarction (MI) is linked to decreased cardiac function and heart failure. Astragaloside IV (AST IV), a component of traditional Chinese medicine, has shown promise in animal studies for improving function. Purpose This study intends investigate the role AST MI its correlation with sirtuin-3 (SIRT3)/β-catenin/peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway. Methods After establishment an model MI, 60 rats were divided into control group, group (MI group), positive (sham low-dose (0.8 mg/100 g), high-dose (3 g). The animals injected once day 4 consecutive weeks. To further mechanism action IV, another nine from randomly 3TYP (5 SKL2001 (20 µmol/L, 10 mL/kg), T0070907 (0.15 three each group. intervened by intraperitoneal injection gavage Hemodynamics, function, ventricular weight, infarct area assessed at 1, 2, weeks post-surgery. collagen content non-infarcted was measured, expression rate transforming growth factor-beta ED-positive cells calculated, reverse transcription polymerase chain reaction used detect SIRT3, β-catenin, PPARγ mRNA expression. Results left ejection fraction, short-axis shortening rate, mass obviously. treatment systolic blood pressure, +dp/dtmax, –dp/dtmax, end-diastolic as well reduced deposition rat hearts ( p < 0.05). inhibited SIRT3/β-catenin/PPARγ pathway when alleviating fibrosis. Intervention SIRT3 blocker 3-TYP, β-catenin agonist SKL2001, reversed inhibitory effect on Conclusion exhibits significant anti-fibrotic effects, effectively reducing model, parameters, decreasing markers such creatine kinase-MB. It significantly regulates exert cardioprotective effects. key involves inhibiting SIRT3/β-catenin/PPARγ, offering innovative strategy post-MI treatment.
Язык: Английский
Процитировано
0
Phytotherapy Research, Год журнала: 2025, Номер unknown
Опубликована: Фев. 6, 2025
ABSTRACT Mitophagy is a process by which cells selectively eliminate damaged or dysfunctional mitochondria through the autophagy–lysosome pathway, thereby maintaining mitochondrial quality and cellular homeostasis. This closely linked to onset progression of various heart diseases. Modern pharmacological research has demonstrated that phytochemicals can regulate homeostasis in cardiomyocytes multiple mechanisms, influencing mitophagy protecting cardiomyocytes, turn exerts anti‐cardiovascular effects. However, underlying mechanisms these effects are not yet fully understood. study summarizes molecular diseases, aiming provide reference for treatment targeting against The results indicated (such as Berberine, Ginsenoside Rg1, Quercetin, Resveratrol, Baicalein, so on) exert preventive therapeutic on diseases cardiac toxicity damage, myocardial ischemia/reperfusion injury, failure, aging, hypertrophy, cardiomyopathy, on.) via regulating PINK1/Parkin FUNDC1‐dependent pathway. These compounds mainly their homeostasis, dynamics, oxidative stress, apoptosis, energy metabolism. provides have effect mitophagy. further in‐depth mechanistic clinical needed future.
Язык: Английский
Процитировано
0
Internal and Emergency Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 16, 2025
Язык: Английский
Процитировано
0
Biomedical Chromatography, Год журнала: 2025, Номер 39(5)
Опубликована: Март 20, 2025
ABSTRACT Qifu decoction (QFD) has shown potential benefits in treating heart failure. However, the mechanism of QFD remains unclear. In this study, myocardial lipidomics, based on ultra‐high‐performance liquid chromatography coupled with an electrospray ionization hybrid quadrupole Orbitrap mass spectrometry (UPLC‐ESI‐Q‐Exactive/MS), was employed to identify therapeutic targets for failure a mice model induced by ligating left anterior descending coronary artery. It found that 47 lipid metabolites were associated failure, which 35 showed significant reversal during treatment. The QFD‐reversed mainly located phosphatidylcholine, lysophosphatidylcholine, sphingomyelin, and ceramide, involved glycerophospholipid sphingolipid metabolism. results Western blotting analysis revealed could effectively alleviate through increasing levels lysophosphatidylcholine acyltransferase 1 (LPCAT1) sphingomyelin synthase (SMS1) reducing acid sphingomyelinase (aSMase) phospholipase A2 (PLA2) regulate metabolic disorders All these be concluded metabolism two crucial target pathways against laid theoretical groundwork its clinical application.
Язык: Английский
Процитировано
0
Journal of Holistic Integrative Pharmacy, Год журнала: 2025, Номер 6(1), С. 91 - 104
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Апрель 4, 2025
Globally, cardiovascular disease (CVD) has emerged as a leading cause of mortality and morbidity. As the world’s population ages, CVD incidence is on rise, extensive attention been drawn to optimizing therapeutic regimens. Acacetin, natural flavonoid derived from various plants, demonstrated have wide spectrum pharmacological properties, such antioxidant, anti-inflammatory, anti-bacterial, anti-tumor activities, well protective effects diverse tissues organs. Recently, increasing numbers studies (mostly preclinical) indicated that acacetin potential might become novel strategy for CVDs. The importance in treatment necessitates systematic comprehensive review its system underlying mechanisms involved. Here, we first provide an overview some basic properties acacetin. Subsequently, multiple CVDs, like arrhythmias, cardiac ischemia/reperfusion injury, atherosclerosis, myocardial hypertrophy fibrosis, drug-induced cardiotoxicity, diabetic cardiomyopathy, hypertension, senescence, are discussed detail. by which exhibits protection appear involve suppressing oxidative stress, reducing inflammation, preventing cardiomyocyte apoptosis endothelial cell regulating mitochondrial autophagy lipid metabolism. Meanwhile, several critical signaling pathways also found mediate against including phosphoinositide 3-kinase/protein kinase B/mechanistic target rapamycin (PI3K/Akt/mTOR), sirtuin 1/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ coactivator-1α (Sirt1/AMPK/PGC-1α), transforming growth factor-β1/small mothers decapentaplegic 3 (TGF-β1/Smad3), B/endothelial nitric oxide synthase (Akt/eNOS), others. Finally, highlight existing problems associated with need be addressed, requirement clinical evidence enhanced bioavailability, promising drug candidate.
Язык: Английский
Процитировано
0